《“简要报告：局部晚期非小细胞肺癌患者免疫检查点抑制剂输注时间的临床结局”勘误》[《JTO临床与研究报告》，第5卷第4期（2024年），100659]
Corrigendum to 'Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC' [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659].
作者信息
Hirata Tsuyoshi, Uehara Yuji, Hakozaki Taiki, Kobayashi Takayuki, Terashima Yuto, Watanabe Kageaki, Yomota Makiko, Hosomi Yukio
机构信息
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Tokyo Medical and Dental University, Tokyo, Japan.
出版信息
JTO Clin Res Rep. 2024 Nov 8;6(1):100761. doi: 10.1016/j.jtocrr.2024.100761. eCollection 2025 Jan.
Abstract
[This corrects the article DOI: 10.1016/j.jtocrr.2024.100659.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.jtocrr.2024.100659。]
相似文献
1
Corrigendum to 'Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC' [JTO Clinical and Research Reports, Volume 5 Issue 4 (2024) 100659].《“简要报告：局部晚期非小细胞肺癌患者免疫检查点抑制剂输注时间的临床结局”勘误》[《JTO临床与研究报告》，第5卷第4期（2024年），100659]
JTO Clin Res Rep. 2024 Nov 8;6(1):100761. doi: 10.1016/j.jtocrr.2024.100761. eCollection 2025 Jan.
2
Corrigendum to 'Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research' [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781].《免疫肿瘤学研究的人源化小鼠模型：综述及对肺癌研究的启示》勘误 [《JTO临床与研究报告》第6卷第3期（2025年）100781]
JTO Clin Res Rep. 2025 Mar 13;6(5):100824. doi: 10.1016/j.jtocrr.2025.100824. eCollection 2025 May.
3
Brief Report: Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC.简短报告：局部晚期非小细胞肺癌患者中免疫检查点抑制剂输注时间的临床结局
JTO Clin Res Rep. 2024 Mar 5;5(4):100659. doi: 10.1016/j.jtocrr.2024.100659. eCollection 2024 Apr.
4
Corrigendum to 'Even With the CROWN Findings, There Remain Multiple First-Line Treatment Options for Patients With Advanced ALK-Positive NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 2 (2025) 150-153].《“即便有CROWN研究结果，晚期ALK阳性非小细胞肺癌患者仍有多种一线治疗选择”的勘误》[《胸部肿瘤学杂志》第20卷第2期（2025年）150 - 153页]
J Thorac Oncol. 2025 May;20(5):680. doi: 10.1016/j.jtho.2025.02.006. Epub 2025 Feb 21.
5
Corrigendum: Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis.勘误：同步放化疗联合免疫检查点抑制剂治疗局部晚期宫颈癌的疗效和安全性：一项系统评价与荟萃分析
Front Immunol. 2024 Nov 20;15:1524791. doi: 10.3389/fimmu.2024.1524791. eCollection 2024.
6
Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival.从不吸烟的非小细胞肺癌作为一个独立实体：临床病理特征与生存情况
Cancer. 2008 Sep 1;113(5):1012-8. doi: 10.1002/cncr.23679.
7
Corrigendum to 'MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC' [Journal of Thoracic Oncology 19 Issue 3 (2024) 434-450].《“MUC1-C是NSCLC中获得性奥希替尼耐药的常见驱动因素”的勘误》[《胸部肿瘤学杂志》第19卷第3期（2024年）434 - 450页]
J Thorac Oncol. 2025 Mar;20(3):399. doi: 10.1016/j.jtho.2024.12.004. Epub 2024 Dec 18.
8
Corrigendum to previous published articles.对先前发表文章的勘误。
Cell Insight. 2025 Jan 11;4(2):100225. doi: 10.1016/j.cellin.2024.100225. eCollection 2025 Apr.
9
Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report.勘误：病例报告：ROS1融合阳性晚期肺腺癌患者对免疫化疗的持久反应：一例病例报告。
Front Pharmacol. 2023 Jul 26;14:1256801. doi: 10.3389/fphar.2023.1256801. eCollection 2023.
10
Corrigendum to "Changing Phenotypes and Clinical Outcomes Over Time in Microscopic Polyangiitis" [ Volume 8, Issue 10, October 2023, Pages 2107-2116].《显微镜下多血管炎随时间变化的表型和临床结局》勘误 [第8卷，第10期，2023年10月，第2107 - 2116页]
Kidney Int Rep. 2024 Feb 1;9(4):1142. doi: 10.1016/j.ekir.2024.01.051. eCollection 2024 Apr.
Zotero 插件